title: Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
abstract: BACKGROUND
  Health related quality of life (HRQOL) is an important outcome after treatment for upper gastrointestinal carcinoma. This study aimed to compare HRQOL in patients with advanced gastric cancer (GC) receiving either a standard or an experimental treatment.
  
  
  METHODS
  Seventy-one patients have been treated in Cancer Institute (Tehran, Iran) with docetaxel, cisplatin, 5 FU (TCF) or epirubicin, cisplatin, 5-FU (ECF) and were followed from Jan 2002 to Jan 2005. End points were response rate, HRQOL and survival. HRQOL was assessed using the EORCT QLQ-C30 at baseline and after the third cycle of chemotherapy.
  
  
  RESULTS
  The baseline HRQOL scores were comparable between two groups. After treatment improvement was seen in a number of items and domains except for cognitive functioning, and diarrhoea. Pain decreased and physical functioning improved in both groups. However, only the TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001). Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups.
  
  
  CONCLUSIONS
  Docetaxel based treatment (TCF) showed better palliation and improvement of global QOL as compared with epirubicin based treatment (ECF). However, it seems that regardless of treatment offered, effective chemotherapy was the most important factor affecting QOL in these patients.
authors.affiliation: Cancer Research Center, Cancer Institute, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran. ssadighi@doctor.com <ssadighi@doctor.com>
authors.forename: Sanambar
authors.initials: S
authors.lastname: Sadighi
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Mohagheghi
authors.forename: Ali
authors.initials: A
authors.lastname: Montazeri
authors.forename: Zahra
authors.initials: Z
authors.lastname: Sadighi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil